Interleukin-8 activates coagulation and correlates with survival after talc pleurodesis

European Respiratory Journal

Volumn 35, Issue 1, 2010, Pages 160-166

  Montes Worboys, A ^a,b   Rodriguez Portal, J A ^b   Arellano Orden, E ^a,b   Digon Pereiras J ^b   Rodriguez Panadero, F ^a,b  

^a Instituto de Biomedicina de Sevilla   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Cytokines; Inflammation; Malignant pleural effusion; Talc; Thrombin antithrombin complex

Indexed keywords

INTERLEUKIN 8; TALC; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; BLOOD CLOTTING; BLOOD SAMPLING; CALIBRATION; CAUSE OF DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; FEMALE; HUMAN; IMMUNOSTIMULATION; IN VITRO STUDY; INCUBATION TIME; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PLEURODESIS; PRIORITY JOURNAL; SURGICAL TECHNIQUE; SURVIVAL RATE; TALC PLEURODESIS; THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; FEMALE; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; SURVIVAL RATE; TALC; YOUNG ADULT;

EID: 75149181853     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00146808     Document Type: Article

References (34)

1. Light RW. Talc for pleurodesis? Chest 2002; 122: 1506-1508.
2. Light RW. Talc should not be used for pleurodesis. Am J Respir Crit Care Med 2000; 162: 2024-2026.
3. Janssen JP. Is thoracoscopic talc pleurodesis really safe? Monaldi Arch Chest Dis 2004; 61: 35-38.
4. Rodriguez-Panadero F, Janssen JP, Astoul P. Thoracoscopy: general overview and place in the diagnosis and management of pleural effusion. Eur Respir J 2006; 28: 409-421.
5. Jannsen JP, Collier G, Astoul P, et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 2007; 369: 1535-1539.
6. Maskell NA, Lee YC, Gleeson FV, et al. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004; 170: 377-382.
7. Froudarakis ME, Klimathianaki M, Pougounias M. Systemic inflammatory reaction after thoracoscopic talc poudrage. Chest 2006; 129: 356-361.
8. Genofre EH, Marchi E, Vargas FS. Inflammation and clinical repercussions of pleurodesis induced by intrapleural talc administration. Clinics 2007; 62: 627-634.
9. Esmon CT. Inflammation and thrombosis. J Thromb Haemost 2003; 1: 1343-1348.
10. Voetsch B, Loscalzo J. Genetic determinants of arterial thrombosis. Arterioscler Thomb Vasc Biol 2000; 24: 216-229.
11. van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol 2002; 116: 173-177.
12. Van Aken BE, Den Heijer M, Bos GM, et al. Recurrent venous thrombosis and markers of inflammation. Thromb Haemostasis 2000; 83: 536-539.
13. Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: The Leiden Thrombophilia study. J Thromb Haemost 2004; 2: 619-622.
14. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798-1801.
15. Johnson K, Aardeen L, Choi Y, et al. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood 1996; 87: 5051-5060.
16. Van der Poll T, Jansen PM, Van Zee KJ, et al. Tumor necrosis factor-α induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. Blood 1996; 88: 9212-9213.
17. Van der Poll T, Büller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-1627.
18. Antony VB, Loddenkemper R, Astoul P, et al. Management of malignant pleural effusions. Official statement of the American Thoracic Society. Am J Respir Crit Care Med 2000; 162: 1987-2001.
19. Rinaldo JE, Owens GR, Rogers RM. Adult respiratory distress syndrome following intrapleural instillation of talc. J Thorac Cardiovasc Surg 1983; 85: 523-526.
20. Bouchama A, Chastre J, Gaudichet A, et al. Acute pneumonitis with bilateral pleural effusion after talc pleurodesis. Chest 1984; 86: 795-797.
21. Kennedy L, Rusch VW, Strange C, et al. Pleurodesis using talc slurry. Chest 1994; 106: 342-346.
22. Rehse HD, Aye WR, Florence GM. Respiratory failure following talc pleurodesis. Am J Surg 1999; 177: 437-440.
23. Campos JR, Werebe EC, Vargas FS, et al. Respiratory failure due to insufflated talc. Lancet 1997; 349: 251-252.
24. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemostasis 1988; 59: 101-106.
25. Psathakis K, Calderon-Osuna E, Romero-Romero B, et al. The neutrophilic and fibrinolytic response to talc can predict the outcome of pleurodesis. Eur Respir J 2006; 27: 817-821.
26. Rodriguez-Panadero F, Segado A, Martin-Juan J, et al. Failure of talc pleurodesis is associated with increased pleural fibrinolysis. Am J Respir Crit Care Med 1995; 151: 785-790.
27. Rodriguez-Panadero F. Current trends in pleurodesis. Curr Opin Pulmonary Medicine 1997; 3: 319-325.
28. Johnson K, Choi Y, DeGroot E, et al. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 1998; 160: 5130-5135.
29. Shoenmarkers SM, Reitsma PM, Spek CA. Blood coagulation factors as inflammatory mediators. Blood Cells Mol Dis 2005; 34: 30-37.
30. Christiansen SC, Naess AI, Cannegieter SC, et al. Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study. PLoS Med 2006; 3: 1414-1419.
31. Galffy G, Mohamed KA, Dowling PA, et al. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res 1999; 15: 367-371.
32. Coussen LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 19-26.
33. Agrenius V, Chmielewska J, WidströmO, et al. Pleural fibrinolytic activity is decreased in inflammation as demonstrated in quinacrine pleurodesis treatment of malignant pleural effusion. Am Rev Respir Dis 1989; 140: 1381-1385.
34. Romero Falcon A, Montes Worboys A, Arellano Orden E, et al. Comparison in effectiveness and proinflammatory mediators between talc doxycycline and tetracycline for pleurodesis in malignant pleural effusions (MPE). Eur Respir J 2006; 28: Suppl. 50, 536s.